Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Mar 21, 2017

Sanofi Announces Results of First-of-Its-Kind Social Experiment Revealing Real-Life Impact of Symptoms on Allergy Sufferers in the U.S.

The makers of Xyzal® Allergy 24HR, now available over-the-counter (OTC) at full prescription strength, are teaming up with Dr. Neeta Ogden to Encourage Allergy Sufferers to 'Wise Up, Rise Up'
- Video 1
- Photos 3
Mar 7, 2017

Sanofi and Regeneron to Present New Phase 3 Praluent® (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions
Mar 4, 2017

Sanofi and Regeneron Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of Dupixent® (dupilumab) in Moderate-to-Severe Atopic Dermatitis

- Late-breaking oral abstract to be presented today at the Annual Meeting of the American Academy of Dermatology -
Feb 27, 2017

Sanofi and Regeneron to Present New Data on Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses
Feb 8, 2017

Appeals Court Grants Stay of Permanent Injunction for Praluent® (alirocumab) During Appeals Process

- Praluent continues to be available to patients in the U.S. -

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.